Express Insight into Bladder Cancer
Can miRNA expression levels improve subtyping and treatment of bladder cancer?
Michael Schubert |
Bladder cancer: the ninth most common cancer worldwide, with nearly half a million new cases diagnosed each year. Unfortunately, less than three-quarters of those receiving a diagnosis will survive five years, and only about half can expect a decade. Why have those survival rates not significantly improved over time? The disease’s heterogeneity may be at least partly to blame, which is why Jun Zhu, Professor of Genetics and Genomic Sciences at the Icahn School of Medicine, opted to investigate a particular subtype of bladder cancer known as p53-like bladder cancer.
Read the full article now
Log in or register to read this article in full and gain access to The Translational Scientist’s entire content archive. It’s FREE!
Or register now - it’s free!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts